We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Does Caffeine Affect the Sensitivity of Adenosine Perfusion Scans?

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00205166
First Posted: September 20, 2005
Last Update Posted: October 29, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Astellas Pharma US, Inc.
Information provided by (Responsible Party):
University of Wisconsin, Madison
September 12, 2005
September 20, 2005
October 29, 2012
June 1999
December 2004   (Final data collection date for primary outcome measure)
This protocol has a specific aim of determining whether prior caffeine administration affects the sensitivity and specificity of adenosine perfusion scintigraphy for detection of impaired coronary vascular reserve. [ Time Frame: Assessment is made at the time of research adenosine perfusion scintigraphy ]
This protocol has a specific aim of determining whether prior caffeine administration affects the sensitivity and specificity of adenosine perfusion scintigraphy for detection of impaired coronary vascular reserve.
Complete list of historical versions of study NCT00205166 on ClinicalTrials.gov Archive Site
determination of caffeine levels in patients instructed to hold caffeine prior to adenosine imaging [ Time Frame: Assess at time of lab sample results obtained ]
determination of caffeine levels in patinets instructed to hol caffiene prior to adenosine imaging
Not Provided
Not Provided
 
Does Caffeine Affect the Sensitivity of Adenosine Perfusion Scans?
Does Caffeine Affect the Sensitivity of Adenosine Perfusion Scans?
We are studying the affect of caffeine on the sensitivity of detecting coronary artery disease (blockages in the blood flow to the heart) with adenosine tracer scans. Adenosine is a drug used routinely in patients to relax heart blood vessels in order to assess for the presence of coronary artery disease. Often, if patients have had caffeine, the adenosine scan is not used because of the belief that caffeine may reduce the ability to detect coronary artery disease. We would like to test whether caffeine affects our ability to detect coronary artery disease with adenosine tracer scanning. We will perform an imaging study of the heart with adenosine after you have received caffeine.
Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Coronary Artery Disease
  • Procedure: Cardiac SPECT imaging Rest and Stress
    adenosine perfusion scintigraphy
  • Drug: Caffeine
    Caffeine 400 mg po
  • Drug: Caffeine
    Caffeine 200 mg po
  • Active Comparator: 1
    Caffeine 400 mg PO 1 hour before adenosine infusion
    Interventions:
    • Procedure: Cardiac SPECT imaging Rest and Stress
    • Drug: Caffeine
  • Active Comparator: 2
    Caffeine 200 mg po one hour before adenosine infusion
    Interventions:
    • Procedure: Cardiac SPECT imaging Rest and Stress
    • Drug: Caffeine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
50
December 2004
December 2004   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients who have already completed rest/stress 99mTc sestamibi or 99mTc tetrofosmin imaging will be given a form describing this protocol and asked to volunteer for the additional scan

Exclusion Criteria:

  • history of asthma, bronchospastic COPD, or renal failure
Sexes Eligible for Study: All
18 Years to 80 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00205166
1999-109
No
Not Provided
Not Provided
University of Wisconsin, Madison
University of Wisconsin, Madison
Astellas Pharma US, Inc.
Principal Investigator: Charles K Stone, MD Univeristy of Wisconsin
University of Wisconsin, Madison
October 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP